Summary
Nicorandil is a nicotinamide derivative with potent vasodilator properties. Oral and sublingual administration of this compound in patients with coronary artery disease resulted in a predominant reduction of afterload and a small decrease in left ventricular preload. The effects of nicorandil in different doses on contractile left ventricular (LV) function, however, are not well defined. The aim of the present study was to assess the effects of nicorandil on hemodynamics, left ventricular volume and function, as well as the LV contractility index dP/dt measured by Millar-tip manometers. A total of 16 patients with coronary artery disease were included in this study. After diagnostic coronary angiography and ventriculography, the patients randomly received either 10 or 20 mg of oral nicorandil. The hemodynamic parameters, cardiac output, and LV end-diastolic and systolic pressures were determined after 15, 30, and 60 minutes, and a second angiogram was performed 60 minutes after administration. The predominant effect was a decrease in the mean aortic pressure with a concomitant decrease in the peripheral arterial resistance. Clinically relevant changes in aortic pressure, systemic vascular resistance, and rate-pressure product, however, were documented only after oral administration of 20 mg nicorandil, as opposed to minimal changes in the 10 mg group. LV volume and cardiac output were not changed significantly. LV contractility remained unchanged during the observation period. The hemodynamic profile of this compound is dose-dependent afterload reduction without a change in contractility. Because there was no concomitant increase in heart rate, calculated oxygen consumption was reduced, especially in the higher dose group.
Similar content being viewed by others
References
Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators.Am J Cardiol 1989;63:18J-24J.
Taira N. Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates. An overview.J Cardiovasc Pharmacol 1987;10(Suppl 8):S1-S9.
Uchida Y, Yoshimoto N, Murao S. Effect of 2-nicotinamidethyl nitrate (SG-75) on coronary circulation.Jpn Heart J 1978;19:112–124.
Nakagawa Y, Takeda K, Katano Y, et al. Effects of 2-nicotinamidethyl nitrate on the cardiovascular system.Jpn Heart J 1979;20:881–895.
Taira N, Satoh K, Yanagisawa T, Imai Y, Hiwatari M. Pharmacological profile of a new coronary vasodilator drug, 2-nicotinamidethyl nitrate (SG-75).Clin Exp Pharmacol Physiol 1979;6:301–315.
Sakai K, Shiraki Y, Nabata H. Cardiovascular effects of a new coronary vasodilator N-(2-hydroxyethyl) niconiamide nitrate (SG-75): Comparison with nitroglycerin and diltiazem.J Cardiovasc Pharmacol 1981;3:139–150.
Kinoshita M, Sakai K: Pharmacology and therapeutic effects of nicorandil.Cardiovasc Drugs Ther 1990;4:1075–1088.
Lamping KA, Gross GJ: Improved recovery of myocardial segment function following a short coronary occlusion in dogs by nicorandil, a potential new antianginal agent, and nifedipine.J Cardiovasc Pharmacol 1985;7:158–166.
Thormann J, Schlepper M, Kramer W, Gottwick M, Kindler M: Effectiveness of nicorandil (SG-75), a new long-acting drug with nitroglycerin effects, in patients with coronary artery disease improved left ventricular function and regional wall motion and abolition of pacing-induced angina.J Cardiovasc Pharmacol 1983;5:371–377.
Kobayashi K, Hakuta T: Effects of nicorandil on coronary hemodynamics in ischemic heart disease: Comparison with nitroglycerin, nifedipine, and propranolol.J Cardiovasc Pharmacol 1987;8:109–115.
Yamazaki J, Ohsawa H, Uchi T, et al. Study of the efficacy of nicorandil in patients with ischemic heart disease using exercise-T1-201 myocardial tomography.Eur J Clin Pharmacol 1993;44:211–217.
Krumenacker M, Roland E. Clinical profile of nicorandil: An overview of its hemodynamic properties and therapeutic efficacy.J Cardiovasc Pharmacol 1992;20(Suppl 3):S93-S102.
Suryapranata H, MacLeod D. Nicorandil and cardiovascular performance in patients with coronary artery disease.J Cardiovasc Pharmacol 1992;20(Suppl 3):S45-S51.
Silke B, Verma SP, Ali MS, Goldhammer E, Taylor SH. Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise-induced angina pectoris.Am J Cardiol 1989;63:49J-55J.
Kambara H, Tamaki S, Nakamura Y, Kawai C. Effects of intravenous administration of nicorandil on cardiovascular hemodynamics and left ventricular function.Am J Cardiol 1989;63:56J-60J.
Coltart DJ, Signy M. Acute hemodynamic effects of single-dose nicorandil in coronary artery disease.Am J Cardiol 1989;63:34J-39J.
Mauser M, Voelker W, Ickrath O, et al. Vergleich der kardiodepressiven Effekte von Nifedipin, Isradipin, Nisoldipin and Felodipin bei Patienten mit koronarer Herzerkrankung.Z Kardiol 1993;82:17–27.
Goldstein RF, Rosing D, Redwood D, et al. Clinical and circulatory effects of isosorbide dinitrate: Comparison with nitroglycerin.Circulation 1982; 43:629–640.
Mauser M, Voelker W, Ickrath O, et al. Myocardial properties of the new dihydropyridine calcium antagonist isradipine compared to nifedipine with or without additional beta blockade in coronary artery disease.Am J Cardiol 1989;63:40–44.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baumbach, A., Braun, U., Döring, G. et al. Double-blind comparison of the acute effects of two relevant doses of oral nicorandil on central hemodynamics, left ventricular function, and myocardial contractility. Cardiovasc Drug Ther 9 (Suppl 2), 213–220 (1995). https://doi.org/10.1007/BF00878468
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00878468